Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) Short Interest Down 36.1% in February

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHWGet Free Report) was the target of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 2,300 shares, a drop of 36.1% from the February 13th total of 3,600 shares. Based on an average daily volume of 43,900 shares, the short-interest ratio is currently 0.1 days.

Reviva Pharmaceuticals Trading Up 11.4 %

Shares of RVPHW stock traded up $0.01 during trading on Monday, hitting $0.07. The company had a trading volume of 9,002 shares, compared to its average volume of 32,720. The stock’s 50-day moving average price is $0.16 and its 200 day moving average price is $0.16. Reviva Pharmaceuticals has a one year low of $0.04 and a one year high of $0.78.

Reviva Pharmaceuticals Company Profile

(Get Free Report)

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.

Further Reading

Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.